Clinical characteristics and survival analysis of eight cases HIV-negative plasmablastic lymphoma
10.3760/cma.j.issn.0253-2727.2017.04.006
- VernacularTitle: 八例HIV阴性的浆母细胞淋巴瘤患者临床特征及转归
- Author:
Xiao HAN
1
;
Lixing HU
;
Mingqi OUYANG
;
Minghui DUAN
;
Daobin ZHOU
Author Information
1. Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, China
- Publication Type:Journal Article
- Keywords:
Plasmablastic lymphoma;
Clinical characteristics;
Treatment outcome
- From:
Chinese Journal of Hematology
2017;38(4):290-294
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To deepen the knowledge of HIV-negative plasmablastic lymphoma (PBL) .
Methods:Medical records from 8 HIV-negative PBL patients diagnosed in Peking Union Medical College Hospital from January 1997 to May 2015 were collected, and the clinical features and prognosis of these patients were analyzed.
Results:All of these 8 patients were diagnosed as HIV-negative PBL, 3 of 8 patients were males, and others were female. The median age was 60 (43-80) year. Among these patients, 4 cases had underlying immunosuppressive state. These patients all had extra-nodular involvement, and 6 cases of them were at stage Ⅳ according to Ann Arbor Staging, 5 patients had bone marrow involvement. CD38 and CD138 were diffusely positive for all patients, while the positive rate of B cell marker including PAX-5 and Bcl-6 were relative low. 5 of 8 patients had been detected for EBV-DNA, and all of them were negative. The median follow-up for the 7 patients receiving chemotherapy and regular follow-ups was 36 (11-57) months, the median progression-free survival (PFS) was 15 (6-52) months, and the median overall survival was 36 (2-52) months. Among these patients, 4 cases had received chemotherapy combined with Bortezomib, showing 3 cases of effective, but it seems to be difficult to keep the long term efficacy, and disease progression occurred in 2, 9, and 21 months after treatment. 2 patients at stageⅠ-Ⅱ were treated effectively, without disease progression and survival, 5 patients at stage Ⅳacquired the efficacy unsustainably, with a median PFS of 10 (2-21) months and a median overall survival of 12 (6-52) months.
Conclusion:HIV-negative PBL is relatively prevalent in elderly patients, and presenting with high invasiveness in clinical, extremely prone to extra-nodular involvement, especially the bone marrow. The immunophenotype of PBL is more resemble to that of plasmacytoma. Patients who were in late stage at diagnosis show poor prognosis.
